Julio Quintanilla
Infectious Disease · Bronx, NYNPI 1932214467
Payments from drug & device makers
Across 327 payments — averaging $46.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Viiv Healthcare Company$4K
- Janssen Products, LP$2K
- Johnson & Johnson$1K
- AbbVie$966
- AstraZeneca$575
- plus $1K from 12 others
What the payments were for
- Consulting fees$3,30022%
- Food & beverage$11,32375%
- Education$4233%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 82 | $5,585 |
| Viiv Healthcare Company | 101 | $3,567 |
| Janssen Products, LP | 14 | $1,617 |
| Johnson & Johnson(2 entities) | 47 | $1,333 |
| AbbVie | 32 | $966 |
| AstraZeneca(2 entities) | 17 | $575 |
| Novo Nordisk | 8 | $262 |
| Amgen | 4 | $210 |
| GSK | 4 | $168 |
| Dexcom, Inc. | 2 | $141 |
| Amarin Pharma, Inc. | 2 | $131 |
| Exact Sciences | 2 | $126 |
| Sanofi | 1 | $122 |
| Phadia US Inc. | 2 | $111 |
| Merck | 4 | $55 |
| Genentech USA, Inc. | 2 | $32 |
| Abbott | 2 | $29 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,046 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DovatoDolutegravir Sodium/Lamivudine | 55 | $180,620 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 42 | $173,725 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 27 | $100,609 |
| PrezcobixDarunavir/Cobicistat | 21 | $50,914 |
| VemlidyTenofovir Alafenamide | 36 | $47,657 |
| JardianceEmpagliflozin | 26 | $34,344 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $29,806 |
| TivicayDolutegravir Sodium | 12 | $26,861 |
| JanuviaSitagliptin Phosphate | 26 | $24,857 |
| TradjentaLinagliptin | 11 | $11,111 |
| OzempicSemaglutide | 12 | $10,670 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $6,104 |
| VascepaIcosapent Ethyl | 14 | $4,796 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 52 | $1,947 |
| Omega-3 Acid Ethyl Esters | 19 | $1,572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Vemlidy, Descovy | $5,585 | $351,798119 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $3,567 | $207,48167 claims |
| Johnson & JohnsonPrezcobix | $1,333 | $50,91421 claims |
| MerckJanuvia | $55 | $24,85726 claims |
| Novo NordiskOzempic | $262 | $10,67012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.
Other infectious disease in Bronx
- Barry ZingmanBronx$1.7M
- Norbert BrauBronx$1.6M
- Robert GrossbergBronx$1M
- Paul RiskaBronx$292K
- Eric MeyerowitzBronx$241K
- Julian Torres IsasigaBronx$232K
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Stephen ThomasSyracuse$6.2M
- Edward WalshRochester$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.